Combination of encorafenib and binimetinib in the treatment of patients with BRAF-mutated advanced melanoma. Case report
- Authors: Orlova K.V.1, Petenko N.N.1, Garanina N.V.1, Demidov L.V.1
-
Affiliations:
- Blokhin National Medical Research Center of Oncology
- Issue: Vol 25, No 1 (2023)
- Pages: 21-27
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132790
- DOI: https://doi.org/10.26442/18151434.2023.1.202192
- ID: 132790
Cite item
Full Text
Abstract
Background. The need to use BRAF and MEK inhibitors in the treatment of patients with metastatic and/or unresectable BRAF + melanoma in certain clinical situations is beyond doubt nowadays. The medical community need more information about the new combination of targeted therapy approved in Russia, further details on the expected efficacy and tolerability, potential differences from the existing combinations.
Aim. To present of the study results and demonstration of our experience with the new generation of targeted therapy – encorafenib and binimetinib combination – in the treatment of patients with metastatic and/or inoperable BRAF+ melanoma.
Materials and methods. We present the clinical case of BRAF+ advanced melanoma patient with multiple metastases in the liver, spleen, mediastinal and abdominal lymph nodes, stomach and bones who is being treated with encorafenib and binimetinib since 2015 with the treatment efficacy and tolerability described in details, as well as the published data on the efficacy and tolerability of this combination from the pivotal phase III study COLUMBUS.
Results. High immediate and long-term efficacy, satisfactory tolerability of encorafenib and binimetinib combination are presented. Updated data on progression-free and overall survival in the COLUMBUS study confirmed the long-term efficacy of COMBO450 therapy in patients with advanced melanoma with BRAF V600 mutation.
Conclusion. New generation of BRAFi and MEKi combination expands options of systemic therapy for patients with metastatic and/or inoperable BRAF+ melanoma.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Kristina V. Orlova
Blokhin National Medical Research Center of Oncology
Author for correspondence.
Email: krisman03@gmail.com
ORCID iD: 0000-0002-0442-5917
Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology
Russian Federation, MoscowNatalia N. Petenko
Blokhin National Medical Research Center of Oncology
Email: n.petenko@gmail.com
ORCID iD: 0000-0002-5692-0223
Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology
Russian Federation, MoscowNatalia V. Garanina
Blokhin National Medical Research Center of Oncology
Email: garanina.natalia.v@gmail.com
ORCID iD: 0000-0002-3036-2753
Radiologist, Blokhin National Medical Research Center of Oncology
Russian Federation, MoscowLev V. Demidov
Blokhin National Medical Research Center of Oncology
Email: demidov.lev@gmail.com
ORCID iD: 0000-0002-8562-6082
D. Sci. (Med.), Prof., Blokhin National Medical Research Center of Oncology
Russian Federation, MoscowReferences
- Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33-44. doi: 10.1016/j.ejca.2019.11.016
- Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626-36. doi: 10.1056/NEJMoa1904059
- Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X
- Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835-44. doi: 10.1016/S0140-6736(20)30934-X
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127-37. doi: 10.1200/JCO.21.02229
- Орлова К.В., Федянин М.Ю., Симаненков К.Э., и др. Эффективность 1-й линии терапии пролголимабом у больных метастатической меланомой в реальной клинической практике: промежуточные результаты наблюдательного исследования FORA «FOrteca Real practice Assessment». Современная онкология. 2022;24(4):413-25 [Orlova KV, Fedyanin M, Simanenkov KE, et al. Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study. Journal of Modern Oncology. 2022;24(4):413-25 (in Russian)]. doi: 10.26442/18151434.2022.4.202035
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. doi: 10.1038/nature00766
- Orlova KV, Ledin EV, Zhukova NV, et al. Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE). Cancers (Basel). 2021;13(11):2529. doi: 10.3390/cancers13112529
- Stuart DD, Li N, Poon DJ, et al. Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor. Cancer Res. 2012;72(Suppl. 8):3790. DOI:1538-7445.AM2012-3790
- Davis J, Wayman M. Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma. J Adv Pract Oncol. 2022;13(4):450-5. doi: 10.6004/jadpro.2022.13.4.7
- Dummer R, Flaherty K, Robert C, et al. Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. J Clin Oncol. 2021;39(Suppl. 15):9507. doi: 10.1200/JCO.2021.39.15_suppl.9507
- Dummer R, Flaherty KT, Robert C, et al. 1041MO 5-year update on COLUMBUS: a randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma. Ann Oncol. 2021;32(5):S872-3. doi: 10.1016/j.annonc.2021.08.1426
- Dummer R, Ascierto PA, Gogas H, et al. Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Ann Oncol. 2017;28(5):v429-30. doi: 10.1093/annonc/mdx377.002
- Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol. 2022;40(36):4178-88. doi: 10.1200/JCO.21.02659